Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2015 Feb;29(1):43-60. doi: 10.1016/j.hoc.2014.09.009.

Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.

Author information

1
Sharon Carpenter Laboratory, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Room 3456, Los Angeles, CA 90033, USA.
2
Sharon Carpenter Laboratory, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Room 3456, Los Angeles, CA 90033, USA. Electronic address: lenz@usc.edu.

Abstract

This article clarifies prognostic and predictive markers in the treatment of colorectal cancer. Multiple chemotherapeutic drugs are approved for metastatic colorectal cancer (mCRC), but available guidelines are often not helpful in directing drug selections. It would be desirable to define patient populations before chemotherapy by biomarkers that predict outcome and toxicities. RAS mutational evaluation remains the only established biomarker analysis in the treatment of mCRC. BRAF mutant tumors are associated with poor outcome. Chemotherapeutic combination therapies still remain the most active treatments in the armamentarium, and future trials should address the need to prospectively investigate and validate biomarkers.

KEYWORDS:

BRAF; Biomarker; Colorectal cancer; KRAS; NRAS

PMID:
25475572
DOI:
10.1016/j.hoc.2014.09.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center